SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCSeptember 30, 2026

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

Pulmonary adverse events affected almost a third of patients with SCLC or NSCLC who received an ADC in clinical trials, according to a meta-analysis published in the Journal of Thoracic Oncology, and pneumonitis or ILD was the toxicity the authors single out as clinically actionable.
Share

In brief

  • A systematic review and meta-analysis of 24 trials, covering 2,855 patients with lung cancer treated with antibody-drug conjugates (ADCs), put the pooled incidence of any-grade pulmonary adverse events at 30.9%.
  • Grade 3 or higher pulmonary adverse events occurred in 6.9% of patients.
  • Pneumonitis or interstitial lung disease (ILD) occurred in 8.0%, with 2.8% at grade 3 or higher.
  • Pulmonary toxicity led to treatment discontinuation in 6.2% of patients, and pulmonary adverse event-related mortality was 1.96%.
  • Pulmonary adverse events of any kind were more frequent in small cell lung cancer (SCLC) than in NSCLC (52.1% vs 22.5%), while pneumonitis was more frequent in NSCLC (12.1% vs 2.8%).

Study at a glance

  • Design: PRISMA-guided systematic review and meta-analysis, registered in PROSPERO (CRD42024543340)
  • Search: MEDLINE, Embase and Cochrane CENTRAL, for studies published up to 2 January 2025
  • Studies: 24 studies (randomised controlled trials and prospective single-arm trials) in SCLC or NSCLC
  • Patients: 4,048 in total, of whom 2,855 were treated with ADCs
  • Primary outcome: pooled incidence of pulmonary adverse events, estimated with random-effects models
  • Any grade: 30.9% (95% CI 21.5 to 42.3)
  • Grade 3 or higher: 6.9% (95% CI 4.6 to 10.3)
  • Not reported: the individual ADCs and trials included, and pooled estimates by drug design feature (in the abstract)

Pulmonary events in 30.9% of ADC-treated patients, grade 3 or higher in 6.9%

These pooled estimates come from 2,855 patients who received an ADC within randomised or prospective single-arm trials, and the confidence interval around the any-grade figure runs from 21.5% to 42.3%.

The width of that interval likely reflects, in part, variation in incidence between trials, which the random-effects model is designed to accommodate. Because single-arm trials have no comparator, the pooled figures describe how often pulmonary events occurred in treated patients. They are not rates in excess of a control arm.

Pneumonitis in 8.0%, and fatal pulmonary toxicity in 1.96%

Pneumonitis or ILD at grade 3 or higher was recorded in 2.8% of patients, and 6.2% stopped treatment because of pulmonary toxicity.

The authors identify pneumonitis and ILD as the key clinically actionable toxicity of this drug class in lung cancer. Pulmonary adverse event-related mortality of 1.96% means that roughly one patient in 50 treated with an ADC in these trials died of a pulmonary adverse event.

More pulmonary events in SCLC, more pneumonitis in NSCLC

Pulmonary adverse events of any grade were reported in 52.1% of patients with SCLC and 22.5% of those with NSCLC (p=0.005), whereas pneumonitis occurred in 12.1% of patients with NSCLC and 2.8% of those with SCLC (p<0.001).

The two comparisons point in opposite directions. A higher overall rate of pulmonary events in SCLC therefore did not translate into a higher rate of pneumonitis, which was the more frequent problem in NSCLC.

These are comparisons between trials, often testing different drugs in different populations. Tumour type in this analysis is therefore partly bound up with which ADCs were studied in which disease, and the difference cannot be attributed to tumour biology alone.

Risk associated with tumour subtype and with the drug itself

The authors conclude that pulmonary adverse events are common and clinically meaningful in patients with lung cancer treated with ADCs, and that the risk of pneumonitis or ILD is influenced by tumour subtype and by drug characteristics.

The literature search closed on 2 January 2025. ADCs are being tested in a growing number of lung cancer trials, so studies reported after that date are outside these estimates.

Sources

  1. Journal of Thoracic Oncology. Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non–Small Cell Lung Cancer: A Systematic Review and Meta-analysis (2026-08-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Christian Rolfo.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf